Today marks a pivotal step in the fight against ALS. In partnership with the The National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS), FDA, AbbVie, The ALS Association, ALS TDI, ALS United Mid-Atlantic, Answer ALS, The Association for Frontotemporal Degeneration (AFTD), Biogen, Critical Path Institute (C-Path), EMD Serono, Inc., GSK, Eli Lilly and Company, Mitsubishi Tanabe Pharma America, QurAlis, and Target ALS, the FNIH announces the launch of the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS), a public-private partnership that promises to bring new hope to patients and their families. #AMPALS will centralize and build the largest data source for #ALS research, enabling faster breakthroughs and accelerating knowledge sharing among investigators. The program aims to develop reliable biomarkers that could allow for earlier detection of ALS and measures to better track disease progression and evaluate potential treatments. ALS is a progressive disease that robs people of their ability to move, speak, eat, and ultimately breathe. It is estimated that ALS affects about 30,000 people in the United States, with 4,000 to 6,000 new cases diagnosed each year. With a life expectancy of just 2-5 years after diagnosis, people with ALS don’t have time to wait. AMP ALS aims to expedite the development of therapies that can significantly improves the lives of people with ALS. With determination and the support of our partners, advocates, champions, and those living with ALS, we can work toward overcoming this devastating disease. Watch the video and learn more about this effort here: https://lnkd.in/ezPGWJFx #BridgestoBreakthroughs #MND #MotorNeuronDisease #AmyotrophicLateralSclerosis
Foundation for the National Institutes of Health
Non-profit Organizations
North Bethesda, MD 10,578 followers
Forging powerful alliances that support the mission of the NIH and advance breakthrough biomedical discoveries.
About us
The mission of the Foundation for the National Institutes of Health (FNIH) is to foster public health through scientific discovery, translational research and the dissemination of research results through specially-configured, high-impact public-private partnerships consistent with the priorities of the National Institutes of Health (NIH). The FNIH is not only involved in large, ambitious initiatives with potentially high impact on the lives of millions of the world’s citizens, but it also supports smaller focused programs in clinical training and ancillary support programs. The FNIH helps to underwrite biomedical initiatives that might not be attractive for private funding alone, or for one reason or another are not appropriate for wholly public funding. The FNIH may take on projects that are particularly risky in terms of the likelihood of success or where companies may be willing to forgo profits because of early stage nature of the program or in the case of some global health initiatives due to the charitable nature of the project. The FNIH's projects tend to be longer-term, operating on a time scale that can be unattractive for private investors. At the same time the foundation is capable of responding quickly and nimbly to funding needs that are immediate and pressing. With the goals of NIH as its guide, the FNIH serves both the public and private sectors, helping them achieve significant breakthroughs in human health in areas of interest that overlap with those of NIH. To learn more about FNIH, its programs and partnership opportunities, or to make a contribution, please visit www.fnih.org
- Website
-
http://www.fnih.org
External link for Foundation for the National Institutes of Health
- Industry
- Non-profit Organizations
- Company size
- 51-200 employees
- Headquarters
- North Bethesda, MD
- Type
- Nonprofit
- Founded
- 1996
- Specialties
- public-private partnership, biomedical research, education and training, collaboration, and program management
Locations
-
Primary
11400 Rockville Pike
Suite 600
North Bethesda, MD 20852, US
Employees at Foundation for the National Institutes of Health
-
Kevin A. Klock
Senior Vice President, Chief Operating Officer and General Counsel, Foundation for the National Institutes of Health
-
Chetan Deshpande
Driving Technological Innovation in Precision Medicine and Healthcare
-
David Carmel
Impatient about getting therapies to those in need
-
Kathy Scarbeck, MA
Health Communications Director | Print & Digital Publishing | News Reporting & Editing | Strategic Planning
Updates
-
REMINDER: Entry deadline is August 30, 2024 The Foundation for the National Institutes of Health proudly introduces the inaugural Kovler Prize for Trust in Life Science Journalism. The award honors an individual who has significantly increased the public’s awareness of and trust in life science through their distinguished body of work in any media. The award includes a $25,000 honorarium, generously funded by the Judy and Peter Blum Kovler Foundation. Journalists from accredited and independent news organizations across the U.S. are eligible to enter. Entries must be submitted by August 30, 2024, at fnih.org/kovlerprize
-
Foundation for the National Institutes of Health reposted this
Blood tests are on verge of transforming the diagnosis and treatment of Alzheimer’s, but they need further validation prior to widespread use in clinical practice. Through a recent head-to-head comparison study and ongoing research, the Foundation for the National Institutes of Health is working to confirm the accuracy of these tests and accelerate the development of treatment options. In the meantime, while there is no sure way to prevent #Alzheimer’s, I spoke with Women’s World and highlighted research suggesting that certain lifestyle choices can help reduce the risk or slow the progression in up to 40% of cases. - Stay mentally active: Engage in brain-challenging activities like puzzles, reading, or learning new skills. - Maintain regular physical exercise: Exercise improves blood flow to the brain, supports cardiovascular health and is associated with a lower risk of cognitive decline. - Have a healthy diet: A Mediterranean diet rich in fruits, vegetables, whole grains and healthy fats is linked to better brain health. - Keep up the social engagement: Regular interaction with family, friends or community groups can help keep your brain active and reduce feelings of loneliness. - Manage your cardiovascular health: Conditions like high blood pressure, diabetes and high cholesterol can increase Alzheimer’s risk. - Prioritize quality sleep: Aim for seven to eight hours of sleep per night. Poor sleep is linked to cognitive decline, and addressing sleep disorders may reduce the risk of dementia. - Avoid Smoking and limit alcohol: Smoking and excessive alcohol consumption are associated with an increased risk of cognitive decline. Links in the comments https://lnkd.in/eNhuYA4X
-
Foundation for the National Institutes of Health reposted this
Groundbreaking research news: CurePSP has joined the Accelerating Medicines Partnership® in Parkinson’s Diseases and Related Disorders (AMP® PDRD). This initiative, led by the Foundation for the National Institutes of Health (FNIH), aims to better differentiate Parkinson’s disease from related neurodegenerative disorders, including progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal degeneration (CBD), to enable earlier diagnoses, more timely interventions and better outcomes. CurePSP is committed to ensuring that this focus on early and accurate diagnosis for PSP, MSA, and CBD drives meaningful progress in improving patient care. We join this effort alongside several other key partners, including Aligning Science Across Parkinson’s | ASAP, C2N Diagnostics, Denali Therapeutics, GSK, The Michael J. Fox Foundation for Parkinson's Research and Sanofi, all working together to push the boundaries of research to make a tangible impact. #PSP #MSA #CBD #Parkinsons #Neurodegeneration #FNIH #CurePSP #EarlyDiagnosis #NIH
-
Foundation for the National Institutes of Health reposted this
I’m excited to share that CurePSP is now part of the Accelerating Medicines Partnership® in Parkinson’s Disease and Related Disorders (AMP® PDRD). This groundbreaking initiative, led by the Foundation for the National Institutes of Health (FNIH), aims to better differentiate Parkinson’s disease from related neurodegenerative disorders, including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD), to enable earlier diagnoses, more timely interventions, and better outcomes. At CurePSP, we are committed to ensuring that this focus on early and accurate diagnosis for PSP, MSA, and CBD drives meaningful progress in improving patient care. We're joining this effort alongside several other key partners, including Aligning Science Across Parkinson’s | ASAP , C2N Diagnostics, Denali Therapeutics, GSK, The Michael J. Fox Foundation for Parkinson's Research , and Sanofi, all working together to push the boundaries of research, and make a real impact. #PSP #MSA #CBD #Parkinsons #Neurodegeneration #FNIH #CurePSP #EarlyDiagnosis #NIH
-
The NIH Common Fund has announced a Notice of Intent to Publish a Funding Opportunity for the Complement Animal Research In Experimentation (Complement-ARIE) Program! The purpose of this Notice is to alert the research community that the Complement-ARIE Program is planning to issue a Notice of Funding Opportunity (NOFO) to support Comprehensive New Approach Methodologies (NAMs) Technology Development Centers. These Centers will stimulate the development of combinatorial NAMs in the areas of greatest need. The estimated release date of the NOFO is: October 18, 2024. View the Complement-ARIE Notice of Intent to Publish a Funding Opportunity: https://go.nih.gov/iiuNC9v Keep up to date with future announcements by joining the Complement-ARIE listserv: https://lnkd.in/eqBFZ9Yy #NAMs #NewApproachMethodologies #BiomedicalResearch #FundingOpportunity
-
Don’t miss the latest edition of Clinical Lab Chat as host Chris Wolski interviews Alessio Travaglia, PhD, PMP, Director of Translational Science, Neuroscience at the FNIH. They explore the future of Alzheimer’s testing and treatment, the promise of blood-based biomarkers, and why we’re on the verge of a golden age in neurology. Listen now to learn how better diagnostics are set to transform patient care. https://lnkd.in/gAjFbHYe
Clinical Lab Chat: From Spinal Taps to Blood-Based Biomarkers: Advances in Alzheimer’s Testing on Apple Podcasts
podcasts.apple.com
-
Reminder: Send in your nominations for the 26th Annual Norman P. Salzman Memorial Awards. This award recognizes the outstanding research of young investigators in the fields of basic and clinical virology. Application forms and Details can be found at https://lnkd.in/gWrcJZKS
-
Foundation for the National Institutes of Health reposted this
I recently came across an incredibly inspiring paper from Carlos Alberto Larrauri, JD, MPA, MSN, the co-chair of Accelerating Medicines Partnership Schizophrenia (AMP SCZ) , where he shares his personal journey with #Schizophrenia. His story is a powerful reminder of why we do what we do and the importance of keeping the voices of those directly impacted at the heart of our efforts. “By bridging the gap between scientific inquiry and human experience, we can develop more effective, personalized treatments and create mental health care delivery and research systems responsive to the needs of those it serves” At the Foundation for the National Institutes of Health, we believe that the voices of those with lived experience are not just important—they are essential. Our work centers around their insights, ensuring that every step we take is guided by the realities they face. https://lnkd.in/ecH7HEGN
Messiah or pariah? Psychosis, science, and finding meaning in lived experience - Schizophrenia
nature.com
-
Foundation for the National Institutes of Health reposted this
Attending #AAIC2024 was an amazing experience! The event was full of groundbreaking advancements, and I was really impressed by the research on biomarkers and by our collective effort toward making a real impact. Some of my main takeaways from this year’s fantastic conference are: 1. Critical Advancements in #BloodBiomarkers for #Alzheimer's Detection: Recent studies have demonstrated that AD blood tests can reliably be used to confirm #amyloid pathology in cognitively impaired individuals. The JAMA article on the successful use of blood-based biomarkers and the Foundation for the National Institutes of Health developed head-to-head study that examined which blood tests most accurately detected amyloid plaques and other AD-related measures, represent a critical milestone toward using blood biomarker to detect AD in primary and secondary care 2. Challenges and Requirements for Comprehensive AD Biomarkers: Biomarkers should be minimally invasive but also robust, accessible, scalable, and generalizable. We must understand how biomarker measures may vary in different ethnic populations or be affected by comorbidities, sex differences, APOE genotype, or medications. In addition, the field needs better biomarkers and tool to detect and track ARIA. 3. Evaluating biomarkers beyond Amyloid and Tau: Beyond amyloid and tau, there is a lot of interest in identifying and validating biomarkers for inflammation, vascular brain injury, and non-AD copathologies in addition to synaptic markers. Progress is being made in developing blood-based assays or imaging methods for detection of AD or non-AD copathology biomarkers, which can be employed for dementia subtyping. The FNIH seeks to validate a PET tracer of the SV2A as a reliable biomarker to measure the progression of AD and the effectiveness of potential treatments, and results are expected in 2025. 4. Subtyping dementia – the need for a specific biosignature for AD disease: Out of clinical trial learnings, earlier is better for treatment. More research is needed to ensure we are testing the right target and right drug at the right stage of AD. The next challenge entails developing a biosignature to identifying AD more efficiently, accurately, and at earlier stages using noninvasive biomarkers. 5. Biomedical research is complex and no single organization can tackle it alone - In these times, the need for collaboration is critical and necessary. I am grateful to all our AD/ADRD partners who work with us to tackle these challenging problems together. Howard Fillit, MD, Mark Roithmayr, Susan Dickinson, Michael Weiner, Sanjay Kumar, Christopher Weber, David Dolby, Glenn A. Harris, Klaus Romero, Danielle Graham, Niranjan Bose, Joel Braunstein, MD (links below) #Neurodegeneration #alzheimers #partnerships #ResearchCollaboration #FNIH #BridgesToBreakthroughs
-
+7